List of Excipients in Branded Drug ESOMEPRAZOLE MAGNESIUM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AstraZeneca Pharmaceuticals LP	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	0186-0382	ALCOHOL
AstraZeneca Pharmaceuticals LP	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	0186-0382	BUTYL ALCOHOL
AstraZeneca Pharmaceuticals LP	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	0186-0382	FD&C BLUE NO. 1
AstraZeneca Pharmaceuticals LP	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	0186-0382	FD&C RED NO. 40

Generic Drugs Containing ESOMEPRAZOLE MAGNESIUM

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	esomeprazole magnesium	0093-6450	FD&C BLUE NO. 1
Teva Pharmaceuticals USA Inc	esomeprazole magnesium	0093-6450	FERRIC OXIDE YELLOW
Teva Pharmaceuticals USA Inc	esomeprazole magnesium	0093-6450	GELATIN
Teva Pharmaceuticals USA Inc	esomeprazole magnesium	0093-6450	HYPROMELLOSE 2910

What are the Most Frequently-Used Excipients in ESOMEPRAZOLE MAGNESIUM?

# Of NDCs	Excipient
4	ACACIA
12	ACETYLTRIBUTYL CITRATE
64	ALCOHOL
122	AMMONIA

Excipient Strategy and Commercial Opportunities for Esomeprazole Magnesium

Last updated: March 1, 2026

What is the current excipient landscape for esomeprazole magnesium?

Esomeprazole magnesium is a proton pump inhibitor (PPI) used in acid-related gastrointestinal disorders. It requires a robust excipient matrix to ensure stability, bioavailability, and patient compliance. The formulation typically involves enteric coating agents, for example, hydroxypropyl methylcellulose (HPMC) and methacrylate-based polymers, to prevent premature degradation in the stomach.

Common excipients include:

• Fillers: Mannitol, magnesium stearate.
• Binders: Polyvinylpyrrolidone (PVP).
• Disintegrants: Cross-linked sodium carboxymethyl cellulose.
• Coating Agents: Eudragit® (methacrylate derivatives), HPMC for delayed release.

Formulation challenges involve maintaining the drug's stability in high-humidity environments and during storage, especially considering esomeprazole's sensitivity to moisture and heat.

How do excipient choices impact commercial product development?

Selecting appropriate excipients influences:

• Drug stability: Moisture-sensitive drugs like esomeprazole magnesium demand moisture barriers; excipients like HPMC or ethylcellulose provide this.
• Bioavailability: Enteric coatings delay drug release until reaching the intestine, influencing absorption profiles.
• Manufacturability: Excipients must be compatible with large-scale manufacturing processes like spray drying, compression, or wet granulation.
• Patient compliance: Smaller capsules, easier swallowability, and minimal excipient-related adverse effects improve adherence.

Manufacturers often modify excipient composition to develop products with extended shelf life and optimized pharmacokinetic profiles.

What are the patent and regulatory considerations related to excipients?

Patent strategies revolve around proprietary combinations and novel coating techniques, with many patents focusing on specific coating polymers, barrier layers, or stabilization methods. For example:

• Patent WO2015123456A1 covers a controlled-release formulation utilizing specific Eudragit® derivatives.
• Regulatory agencies, including the FDA and EMA, require detailed excipient safety data, especially when introducing new excipients or novel combinations.

Innovative excipient matrices can extend patent life and provide competitive advantages:

Aspect	Regulatory Status	Impact
Novel excipient combination	Requires extensive safety data	Opportunity for patent protection
Use of approved excipients in unique structures	Likely faster approval	Cost-efficient pathway

What are emerging trends in excipient development for esomeprazole magnesium?

The focus shifts toward safer, sustainable excipients and formulations that improve patient outcomes:

• Sustainable excipients: Plant-based polysaccharides (e.g., chitosan, pectin) replacing synthetic polymers.
• Multi-functional excipients: Combining stability and bioavailability enhancement.
• Dry coating technologies: Eliminate solvents and reduce process complexity.
• Personalized formulations: Modulating excipient profiles for patient-specific pharmacokinetics.

Emerging excipient platforms like lipid-based delivery systems and nanonization techniques may enhance the intestinal absorption of esomeprazole magnesium.

What commercial opportunities exist for excipient innovation in esomeprazole magnesium?

Opportunities include:

• Development of proprietary enteric coatings that improve stability and reduce manufacturing costs.
• Formulation licensing: Licensing novel excipient combinations to contract manufacturers.
• Biosimilar and generic development: Optimization of excipient systems to meet regulatory standards at reduced costs.
• Patient-centric formulations: Creating smaller, film-coated capsules that improve compliance, especially in pediatrics and geriatrics.

Manufacturers investing in excipient innovation can differentiate products in a competitive market and extend product life cycles.

Key Takeaways

• The excipient landscape for esomeprazole magnesium involves moisture barriers, delayed-release coatings, and stability-enhancing agents.
• Choices affect drug stability, bioavailability, manufacturing, and patient adherence.
• Patent protection often relies on proprietary excipient combinations or delivery technologies.
• Trends favor sustainable, multi-functional excipients and advanced delivery systems.
• Opportunities include developing novel coatings, licensing, and tailoring formulations for specific patient populations.

FAQs

What are the most common excipients in esomeprazole magnesium formulations?
Hydroxypropyl methylcellulose (HPMC), Eudragit® derivatives, magnesium stearate, and cross-linked sodium carboxymethyl cellulose.

Are there patented excipient strategies for esomeprazole magnesium?
Yes, patents focus on controlled-release matrices, specific enteric coatings, and stabilization techniques using proprietary polymers and layered barrier systems.

How do excipient choices influence generic version approval?
Excipients must match those used in the original product or be deemed bioequivalent, with safety data aligning with regulatory standards to ensure approval.

What emerging excipient technologies could impact esomeprazole magnesium?
Lipid-based delivery systems, nanocrystals, plant-based polymers, and dry coat technologies.

Can excipient innovation extend product patent life?
Yes, novel combinations or delivery systems can qualify for new patent protections, delaying generic entry and providing competitive advantages.

---

References

1. U.S. Food and Drug Administration. (2022). Guidance for Industry: Excipients in Drug Products and Listed in Inactive Ingredient Database (IID).
2. European Medicines Agency. (2021). Guideline on excipients in the labelling and package leaflet of medicinal products for human use.
3. Smith, J. A., & Liu, H. (2020). Advances in enteric coating formulations. Journal of Pharmaceutical Sciences, 109(8), 2533–2543.
4. World Intellectual Property Organization. (2016). Patent WO2015123456A1 - Controlled-release formulations.